Unicycive Therapeutics (UNCY) Projected to Release Quarterly Earnings on Wednesday

Key Points

• Unicycive Therapeutics is expected to report Q3 2026 results before the market opens Wednesday, November 11. Analysts forecast a loss of $0.33 per share and revenue of $0.90 million; the earnings call is scheduled for November 12 at 9:30 a.m. ET.
• In its prior quarter, the company reported a loss of $0.06 per share, beating the consensus estimate of a $0.47 loss by $0.41. Analysts expect a full-year loss of $1.16 per share.
• Analyst sentiment is mixed but averages to a “Moderate Buy”, with a consensus price target of $18.25. Shares opened at $3.73, well below their 52-week high of $8.74.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Unicycive Therapeutics to announce earnings of ($0.33) per share and revenue of $0.90 million for the quarter. Interested persons can find conference call details on the company's upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 9:30 AM ET.

Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.41. On average, analysts expect Unicycive Therapeutics to post ($1.16) EPS for the current fiscal year and $1.44 EPS for the next fiscal year.

Unicycive Therapeutics Stock Up 3.8%

UNCY opened at $3.73 on Wednesday. The company has a market cap of $103.77 million, a P/E ratio of -2.12 and a beta of 1.91. The firm's 50-day moving average price is $4.46 and its 200-day moving average price is $6.06. Unicycive Therapeutics has a 52-week low of $3.33 and a 52-week high of $8.74.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Unicycive Therapeutics in a report on Friday, September 4th. B. Riley Financial reaffirmed a "buy" rating and set a $20.00 target price (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Wall Street Zen upgraded shares of Unicycive Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 15th. Zacks Research raised shares of Unicycive Therapeutics from a "strong sell" rating to a "hold" rating in a research note on Wednesday, August 19th. Finally, HC Wainwright cut their price target on shares of Unicycive Therapeutics from $15.00 to $13.00 and set a "buy" rating for the company in a report on Tuesday, September 29th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $18.25.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc NASDAQ: UNCY is a clinical-stage biotechnology company focused on developing treatments for kidney disease and related metabolic complications. The company's primary focus is hyperphosphatemia, an excess of phosphate in the blood that commonly affects people with chronic kidney disease, particularly those receiving dialysis.

Unicycive's lead product candidate is oxylanthanum carbonate (OLC), an investigational, orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.